In fact, members of the SLC25A family (e.g. SLC25A4/5/6) are existent drug targets for the treatments of bone metastases in breast cancer and metastatic bone disease [46]; since prostate cancer also exhibit bone metastasis [3], SLC25A22 may be worth being examined for potential relations to the metastatic properties of prostate cancer. This evidence concerns the gene SLC25A4 and prostate cancer.